Abstract
CD73 is a novel immune checkpoint associated with adenosine metabolism that promotes tumor progression by suppressing antitumor immune response and promoting angiogenesis. The inhibition of CD73, in combination with immune checkpoint blockade, targeted therapy or conventional therapy, improves antitumor effects in numerous preclinical mouse models of cancer. Emerging evidence suggests that the combination of anti-CD73 and immune checkpoint blockade has promising clinical activity in patients with advanced solid tumors. In this review, we will discuss the specific role of CD73 on both tumor cells and nontumor cells in regulating tumor immunity and tumorigenesis and provide an update on the current view of the antitumor activity of targeting CD73 by mAb or small molecule selective inhibitors in preclinical and clinical settings.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 983-997 |
| Number of pages | 15 |
| Journal | Immunotherapy |
| Volume | 11 |
| Issue number | 11 |
| DOIs | |
| State | Published - 2019 |
Funding
This research was in part supported by National Institutes of Health (grant numbers CA149669, CA208354 and CA222963) P50CA221747 SPORE Pilot, Melanoma Research Alliance Pilot Award, the Marsha Rivkin Center for Ovarian Cancer Research Pilot Award, CBC HTS Supplemental Grant to B Zhang, Northwestern University RHLCCC Flow Cytometry Facility, a Cancer Center Support Grant (grant number NCI CA060553), the RH Lurie Comprehensive Cancer Center. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Keywords
- CD73
- adenosine receptor
- immune checkpoint blockade
- immunotherapy
- tumor evasion
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology
